indazoles has been researched along with capecitabine in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| Chen, Y; Cohen, RB; Herbst, RS; Kim, S; Kozloff, MF; Martin, LP; Olszanski, AJ; Rado, T; Rosbrook, B; Samuel, TA; Starr, A; Tarazi, J; Tortorici, M | 1 |
| Adams, LM; Botbyl, J; Brady, J; Chau, I; Corrie, P; Digumarti, R; Laubscher, KH; Mallath, M; Midgley, RS | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Ahn, S; Kang, WK; Kim, KM; Kim, ST; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Jung, SH; Kang, WK; Kim, ST; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Domchek, SM | 1 |
| Edeline, J; Frenel, JS; Gilabert, M; Raoul, JL; Senellart, H | 1 |
| Alifieris, CE; Avgoustou, C; Delis, SG; Griniatsos, J; Nikolaou, M; Panagiotidis, MI; Souferi-Chronopoulou, E; Trafalis, DT | 1 |
3 review(s) available for indazoles and capecitabine
| Article | Year |
|---|---|
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
[Proton pump inhibitors and cancers: A hazardous association?]
Topics: Antineoplastic Agents; Bacterial Infections; Capecitabine; Contraindications, Drug; Drug Interactions; Dysbiosis; Erlotinib Hydrochloride; Fractures, Bone; Gastrointestinal Absorption; Gastrointestinal Neoplasms; Gefitinib; Humans; Indazoles; Kidney; Neoplasms; Prognosis; Protein-Tyrosine Kinases; Proton Pump Inhibitors; Pyrimidines; Sulfonamides | 2020 |
6 trial(s) available for indazoles and capecitabine
| Article | Year |
|---|---|
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Taxoids; Treatment Outcome | 2012 |
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Indazoles; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate | 2013 |
Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Disease Progression; Female; Humans; Indazoles; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Stomach Neoplasms; Sulfonamides; Young Adult | 2016 |
Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Follow-Up Studies; Humans; Indazoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Pyrimidines; Stomach Neoplasms; Sulfonamides; Young Adult | 2016 |
Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Indazoles; Irinotecan; Male; Middle Aged; Oxaliplatin; Progression-Free Survival; Pyrimidines; Sulfonamides | 2020 |
1 other study(ies) available for indazoles and capecitabine
| Article | Year |
|---|---|
The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Female; Furans; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Indoles; Ketones; Mutation; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Vinblastine; Vinorelbine | 2018 |